Abstract: The present disclosure provides methods of treating or reducing the symptoms of muscular dystrophy in a human patient between the age of 1 day and 18 years old, comprising administering to the human patient in need thereof a therapeutically effective amount of a vamorolone and/or a salt thereof.

Abstract: The present invention relates to compounds and methods which may be useful as treatments of diseases.

Abstract: Provided is a tartrate salt of 3-(1H-indol-5-yl)-5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-b]pyridine and crystalline forms thereof. Also provided are pharmaceutical compositions comprising a tartrate salt disclosed herein and crystalline forms thereof and a pharmaceutically acceptable excipient, and a method of treating a disease or disorder, such as disease or disorder associated with neuroinflammation, comprising administering to a subject in need thereof, a therapeutically effective amount of an acid addition salt disclosed herein or the pharmaceutical composition of the acid addition salt.

Abstract: Provided is an aqueous oral pharmaceutical suspension composition comprising vamorolone Form I. Also provided are methods for its preparation and its use.

Abstract: Provided are certain polymorphic forms of vamorolone as well as pharmaceutical compositions and methods for their use.

Abstract: Provided is an acid addition salt of 3-(1H-indol-5-yl)-5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-b]pyridine selected from a tartrate salt, a phosphate salt, and a fumarate salt. Also provided are pharmaceutical compositions comprising an acid addition salt disclosed herein and a pharmaceutically acceptable excipient, and a method of treating a disease or disorder, such as disease or disorder associated with neuroinflammation, comprising administering to a subject in need thereof, a therapeutically effective amount of an acid addition salt disclosed herein or the pharmaceutical composition of the acid addition salt.

Abstract: Provided is an aqueous oral pharmaceutical suspension composition comprising vamorolone Form I. Also provided are methods for its preparation and its use.

Abstract: The present invention relates to compounds and methods which may be useful as treatments of diseases.

Abstract: Provided is an aqueous oral pharmaceutical suspension composition comprising vamorolone Form I. Also provided are methods for its preparation and its use.

Abstract: Provided is an aqueous oral pharmaceutical suspension composition comprising vamorolone Form I. Also provided are methods for its preparation and its use.

Abstract: The present disclosure provides methods of treating or reducing the symptoms of muscular dystrophy in a human patient between the age of 1 day and 18 years old, comprising administering to the human patient in need thereof a therapeutically effective amount of a vamorolone and/or a salt thereof.

Abstract: The present invention relates to compounds and methods which may be useful as treatments of diseases.

Abstract: The present invention relates to compounds and methods which may be useful as treatments of diseases.

Abstract: Provided is an aqueous oral pharmaceutical suspension composition comprising vamorolone Form I. Also provided are methods for its preparation and its use.

Abstract: The present invention relates to compounds and methods which may be useful as treatments of diseases.

Abstract: The present invention relates to compounds and methods which may be useful as treatments of diseases.

Abstract: The present invention relates to compounds and methods which may be useful as treatments of diseases.

Abstract: The present invention relates to compounds and methods which may be useful as treatments of diseases.